{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:57:31Z","timestamp":1774569451138,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1097\/fpc.0000000000000377","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T16:01:44Z","timestamp":1560873704000},"page":"155-157","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacogenetic testing for the treatment of aspergillosis with voriconazole in two HIV-positive patients"],"prefix":"10.1097","volume":"29","author":[{"given":"Patricia P.","family":"Fulco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Beaulieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Higginson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Bearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciw326","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R2-4-20210214","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R4-4-20210214","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1345\/aph.1K530","article-title":"Complexity of interactions between voriconazole and antiretroviral agents","volume":"42","author":"Yakiwchuk","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R5-4-20210214","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics","volume":"34","author":"Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R6-4-20210214","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/cpt.1012","article-title":"Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults","volume":"104","author":"Mangal","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R7-4-20210214","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/QAD.0b013e32834babc9","article-title":"Concurrent atazanavir and voriconazole in a patient with multi-drug resistant HIV and a mycetoma","volume":"25","author":"Gibson","year":"2011","journal-title":"AIDS"},{"key":"R8-4-20210214","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0956462414549035","article-title":"Drug interactions between voriconazole, darunavir\/ritonavir and tenofovir\/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess","volume":"26","author":"Becker","year":"2015","journal-title":"Int J STD AIDS"},{"key":"R9-4-20210214","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2217\/pgs.14.92","article-title":"Voriconazole and atazanavir: a CYP2C19 dependent drug-drug interaction","volume":"15","author":"Calgano","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R10-4-20210214","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/jcph.798","article-title":"CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects","volume":"57","author":"Zhu","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R11-4-20210214","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-6405-11-25","article-title":"Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity","volume":"11","author":"Bouatou","year":"2014","journal-title":"AIDS Res Ther"},{"key":"R12-4-20210214","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/jac\/dkv449","article-title":"Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient","volume":"71","author":"Ambrosioni","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R13-4-20210214","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"R14-4-20210214","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R15-4-20210214","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2016 recommendations of the international antiviral society \u2013 USA panel","volume":"316","author":"Gunthard","year":"2016","journal-title":"JAMA"},{"key":"R16-4-20210214","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R17-4-20210214","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","article-title":"Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir","volume":"80","author":"Mikus","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R18-4-20210214","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2146\/news180036","article-title":"Pharmacogenetics tools readily available for those who opt to use them","volume":"75","author":"Traynor","year":"2018","journal-title":"Am J Health Syst Pharm"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01213011-201908000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T15:30:49Z","timestamp":1614353449000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201908000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000377","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}